Exhibit 99.1

VIRTUAL INVESTOR AND ANALYST EVENT November 3, 2020

DI S CLAIM ER 2 This presentation has been prepared by the Company . “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting . By receiving this presentation and/or attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations . This presentation is being made only to, and is directed only at, (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19 ( 5 ) of the United Kingdom Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) (the “Order”) ; (ii) high net worth bodies corporate, unincorporated associations, partnerships and trustees of high value trusts as described in Article 49 ( 2 )(a) - (d) of the Order ; (iii) “overseas recipients” as defined in Article 12 of the Order ; (iv) persons in member states of the European Economic Area (the “EEA”) who are qualified investors, as defined in the Prospectus Regulation (Regulation (EU) 2017 / 1129 ) (as amended) ; (v) qualified institutional buyers in the United States as defined in Rule 144 A of the United States Securities Act of 1933 ; or (vi) persons to whom it would otherwise be lawful to distribute it (all such persons being “Relevant Persons”) . Persons who receive this communication (other than Relevant Persons) should not rely on or act upon the contents of this presentation and should return this document immediately . This presentation is being directed only at Relevant Persons and any investment or investment activity to which this presentation relates will be engaged in only with Relevant Persons . This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this presentation or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment activity (including within the meaning specified in section 21 of the United Kingdom Financial Services and Markets Act 2000 ), nor does it constitute a recommendation regarding the securities of the Group . Securities of the abovementioned persons or any of their respective affiliates have not been registered under United States securities laws and may not be offered or sold in the United States absent registration under such laws or unless exempt from registration under such laws . Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance . Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel . Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in the United States, Canada, Australia, Japan or any other jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation . Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions . Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you . No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this presentation . No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this presentation or any other written or oral information which has been or may be made available . Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them . No duty of care is owed or will be deemed to be owed to any person in relation to the presentation . No reliance whatsoever may be placed on the presentation for any purpose . The Company’s shares are currently admitted to trading on public exchanges and, therefore, certain of the information in this presentation could constitute inside information and/or price sensitive information . By accepting this presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws . The information contained in this presentation has not been independently verified . The information in this presentation includes forward - looking statements, made in good faith, which are based on the Group’s or, as appropriate, the Group’s directors' current expectations and projections about future events . These forward - looking statements may be identified by the use of forward - looking terminology including, but not limited to, the terms "believes", "estimates", "plans", "projects", "anticipates", "expects", "intends", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussion of the Group’s strategy, plans, operations, financial performance and condition, objectives, goals, future events or intentions . These forward - looking statements, as well as those included in any other material discussed at the meeting, are subject to risks, uncertainties and assumptions about the Group and investments many of which are outside of the Group’s control, including, among other things, the development of its business, the trends in its operating industry, changing economic, financial, or other market conditions and future capital expenditures . In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward - looking statements may differ materially from those indicated in these statements . Forward - looking statements may, and often do, materially differ from actual results . Thus, these forward - looking statements should be treated with caution and the recipients of the presentation should not place undue reliance on any forward - looking statements . None of the future projections, expectations, estimates or prospects or any other statements contained in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation . Nothing contained in this presentation shall be deemed to be a forecast, projection or estimate of the Company’s future financial performance . The Company’s past performance cannot be relied on as a guide to future performance . Any forward looking - statements are made as of the date hereof . The information and opinions contained in this presentation and any other material discussed verbally are provided as at the date of this presentation and are subject to verification, completion and change without notice . The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified . Subject to obligations under the AIM Rules for Companies published by London Stock Exchange plc and the Market Abuse Regulation (Regulation (EU) 596 / 2014 ) (each as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward - looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise . In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent . Certain industry and market data contained in this presentation has been obtained from third party sources . Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data . While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein . In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates . While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice . This presentation may include certain combined or pro forma financial information for the Company . Such combined or pro forma financial information is preliminary in nature, remains subject to change and is provided solely for illustrative purposes . No reliance should be placed on the combined or pro forma financial information contained in this presentation . By requesting to receive and reviewing this document, you agree to be bound by the foregoing limitations and conditions and, in particular, will be deemed to have represented, warranted and undertaken that you have read and agree to comply with the contents of this disclaimer . The Amryt logo, MYALEPT®, MYALEPTA®, JUXTAPID®, LOJUXTA®, FILSUVEZ® and other trademarks or service marks of Amryt appearing in this presentation are the property of Amryt . This presentation includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations . Solely for convenience, trademarks, tradenames and service marks referred to in this presentation appear without the ®, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law . We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties . FILSUVEZ® (Oleogel - S 10 /formerly known as AP 101 ) is currently an investigational product and has not received regulatory approval by the FDA or EMA . Elements of this presentation only apply in the event that FILSUVEZ® is approved by the appropriate regulatory authorities .

KOL BIOGRAPHIES Prof Jemma Mellerio, MD Prof Jemma Mellerio trained in dermatology in South London at St John’s Institute of Dermatology and King’s College Hospital . Undertaking her MD at St John’s Institute on Genotype - Phenotype Correlations in EB sparked an interest in genetic skin fragility disorders that has endured . She has been a consultant dermatologist since 2003 and is based at St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital, London where she is Chief of Dermatology and leads the Adult EB Service which provides clinical care for around 500 individuals with EB . She also worked as the dermatologist to the Paediatric EB Service at Great Ormond Street Hospital for almost 15 years until recently . Jemma’s clinical interests are EB, Mendelian genodermatoses, and general paediatric dermatology . She has established a large tertiary referral service at St John’s for both adults and children with genetic skin disease, overseeing the care of a large cohort of patients with ichthyosis, palmoplantar keratodermas, other disorders of keratinisation and ectodermal dysplasias . She has active clinical and laboratory research interests in many different aspects of genetic skin disease including gene discovery and phenotyping, a longitudinal prospective study in recessive dystrophic EB, and translational research of new therapies for genodermatoses including cell and gene therapy . She has published widely and lectured nationally and internationally on these areas . 3

KOL BIOGRAPHIES Brett Kopelan Brett Kopelan was initiated into the world of rare diseases ten years ago when his daughter was born with a severe form of Recessive Dystrophic Epidermolysis Bullosa (“RDEB”) . Shortly after her birth, Brett was elected to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) . Upon returning to New York City after his daughter was the 8 th child in the world to undergo a stem cell transplant in hopes of treating her RDEB, he became the Executive Director of debra of America, the only national not - for - profit providing all - inclusive support to the EB community . He currently serves as : President of the board of directors of the Coalition of Skin Diseases ; Treasurer on the board of directors of debra international (a consortium of 55 nongovernmental organizations dedicated to curing EB) ; and Secretary on a 50 - year - old financial services firm's board of directors . Brett also formerly served as both the Chairman of the board of directors, and as the treasurer of the National Organization for Rare Disorders (“NORD”) . Prior to his rare disease work, Brett was an accomplished entrepreneur, starting three different companies raising more than $ 30 million in venture financing, where he led business development and marketing . He has a graduate degree from Columbia University and an undergraduate degree from New York University . 4

KOL BIOGRAPHIES Jimmy Fearon Jimmy Fearon is CEO of DEBRA Ireland and Vice President of DEBRA International . Jimmy has worked for ten years as CEO of DEBRA Ireland . From an organisational perspective, his focus is simply - what does really good look like? How do we get there? In DEBRA's case good looks like closing the gap between what the patients need and what they receive from the state . The gap is wide . To this end DEBRA has established the EB Community Care Programme to create a high standard of support in the home and community . Good also looks like finding a cure and better treatments for the people currently living with EB . To this end, DEBRA has invested in numerous research projects partnering with other DEBRA’s around the world through DEBRA International . Jimmy has worked hard to create an organisation that is in constant pursuit of excellence, and one that identifies opportunities and converts them to outputs for patients and their families . His ability to bring about improvement is based on his previous work experience with KPMG and their blue - chip client base and with Dataconversion Direct where he provided long - term business solutions to organisations like Paddy Power, Unilever, Bank of Ireland, Sky, Dell and Tesco . His board experience includes IDMA, IPOSSI, DEBRA International and Dataconversion Direct . Prior to joining the charity sector Jimmy worked as a volunteer for the Irish Cancer Society, St Vincent De Paul Homeless Shelter and Rotary . 5

Welcome & Opening Remarks • 08:30 AM FILSUVEZ ® Phase 3 EASE Study Results • 08:35 AM Q&A Session with KOLs • 09:15 AM FILSUVEZ ® Launch Readiness • 09:45 AM Q&A Session and Close • 10:15AM – 10:30AM Joe Wiley, MD Chief Executive Officer Mark Sumeray, MD Chief Medical Officer Tracy Cunningham, MD VP, Head of Development Prof Jemma Mellerio Brett Kopelan Jimmy Fearon David Allmond Chief Business Officer 6 AGENDA (EASTERN STANDARD TIME)

FILSUVEZ ® PHASE 3 EASE STUDY RESULTS EFFICACY AND SAFETY OF OLEOGEL - S10 FOR EPIDERMOLYSIS BULLOSA Final Results of Double - Blind randomised controlled Phase (DBP) NCT03068780, EudraCT 2016 - 002066 - 32 Sponsored by Amryt Research Ltd Dr Mark Sumeray, Chief Medical Officer, Amryt Dr Tracy Cunningham, VP, Head of Development, Amryt

DYSTROPHIC & JUNCTIONAL EB - MOST SEVERE EXTENSIVE SKIN INVOLVEMENT EPIDERMOLYSIS BULLOSA (EB) JUNCTIONAL • Most severe form of EB • Extensive blistering all over body • Often fatal in early childhood DYSTROPHIC • Severe form of EB • Fusion of fingers and toes • Possibility of skin cancer SIMPLEX • Mildest form of EB • Episodic blistering Dis ea s e severity 8

58 SITES INITIATED IN 28 COUNTRIES – 223 PATIENTS ENROLLED Argentina – 3 sites Australia – 4 sites Austria – 1 site Belgium – 1 site Brazil – 3 sites Chile – 1 site Colombia – 1 site Croatia – 1 site Czech Republic – 1 site Denmark – 1 site France – 3 sites Georgia – 1 site Germany – 3 sites Greece – 1 site Hong Kong – 1 site Hungary – 1 site Ireland – 2 sites Israel – 1 site Italy – 3 sites Romania – 1 site Russia – 2 sites Serbia – 1 site Singapore – 1 site Spain – 4 sites Switzerland – 1 site UK – 2 sites Ukraine – 1 sites USA – 12 sites 9

Primary endpoint: The proportion of patients with first complete closure of the target wound within 45 days EASE STUDY DESIGN – AGREED WITH FDA AND EMA Subtype Target wound size, cm 2 DEB 10 – <20 20 – <30 30 – 50 10 – <20 JEB/Kindler syndrome 20 – <30 30 – 50 Initiated in 58 sites in 28 countries. The largest Phase 3 conducted in EB Stratified randomisation (1:1) by EB subtype and target wound size (N=223) Screening and enrolment (N=252) Oleogel - S10 + standard of care dressing* (n=109) Control gel + standard of care dressing* (n= 114) Double - blind phase (90 “ 7 days) Open - label phase (24 months ) Oleogel - S10 + standard of care (n=205) *Oleogel - S10/control gel applied at least every 4 days EASE: NCT03068780, EudraCT 2016 - 002066 - 32 DEB, dystrophic EB; EB, epidermolysis bullosa; JEB, junctional EB 10

PATIENT DISPOSITION 11 Assessed for eligibility (N=252) Excluded (n=29) • Not meeting inclusion criteria (n=29) Randomized (n=223) Allocated to Oleogel - S10 (n=109) • Received treatment in DBP (n=109; 100.0%) • Completed DBP (n=100; 91.7%) Allocated to Control Gel (n=114) • Received treatment in DBP (n=114; 100.0%) • Completed DBP (n=99; 86.8%) Allocation (DBP) Discontinued from DBP (n=9; 8.3%) • AE (n=3; 2.8%) (1) • Investigator’s Decision (n=1; 0.9%) • Other (n=3; 2.8%) • Withdrawal of Consent (n=2; 1.8%) • Discontinued from DBP ( n=15; 13.2%) • AE (n=2; 1.8%)(2) • Investigator’s Decision (n=2; 1.8%) • Other (n=3; 2.6%) • Pregnancy (n=1; 0.9%) • Use of Non - permitted Con Med (n=1, 0.9%) • Withdrawal of Consent (n=4, 3.5%) • Worsening of EB Target Wound (n=2; 1.8% ) Continued to OLP (n=100; 91.7%) • Discontinued from OLP (n=25; 22.9%) • Completed OLP (n=9; 8.3%) • Ongoing in OLP (n=66; 60.6%) Continued to OLP ( n=105; 92.1%) • Discontinued from OLP (n=27; 23.7%) • Completed OLP (n=10; 8.8%) • Ongoing in OLP (n=68; 59.6%) Continuation (OLP) Discontinued from OLP (n=25; 22.9%) • AE (n=6; 5.5%) (3) • Other (n=5; 4.6%) • Withdrawal of Consent (n=14; 12.8%) • Death (n=4; 3.7%) Discontinued from OLP (n=27; 23.7%) • AE (n=7; 6.1%) (4) • Non - Compliance (n=1; 0.9%) • Other (n=5; 4.4%) • Progression of Medical Condition (n=1; 0.9%) • Withdrawal of Consent (n=13; 11.4%) • Death (n=2; 1.8%)

EASE STUDY: MAJORITY PEDIATRIC, RDEB, UNDERWEIGHT *Patients with EB simplex (EBS; n=2) were enrolled but excluded following the implementation of protocol V4 BMI, body mass index; DEB, dystrophic EB; EB, epidermolysis bullosa; JEB, junctional EB Category Ole og el - S 1 0 (n=109), n (%) Control gel (n=114), n (%) All patients (N=223), n (%) Age groups 0 – <4 years 7 (6.4) 10 (8.8) 17 (7.6) 4 – <12 years 42 (38.5) 43 (37.7) 85 (38.1) 70% 12 – <18 years 25 (22.9) 29 (25.4) 54 (24.2) ≥18 years 35 (32.1) 32 (28.1) 67 (30.0) Gender Male 68 (62.4) 66 (57.9) 134 (60.1) Female 41 (37.6) 48 (42.1) 89 (39.9) EB subtype* Recessive DEB 91 (83.5) 84 (73.7) 175 (78.5) Dominant DEB 6 (5.5) 14 (12.3) 20 (8.97) JEB 11 (10.1) 15 (13.1) 26 (11.7) BMI group Underweight 56 (51.4) 59 (51.8) 115 (51.6) Normal 45 (41.3) 41 (36.0) 86 (38.6) Overweight 5 (4.6) 6 (5.3) 11 (4.9) Obese 3 (2.8) 8 (7.0) 11 (4.9) 12

EB SUBTYPE – MAJORITY OF RDEB IS GENERALISED SEVERE 13 Ole og el - S 1 0 (N = 109) n (%) Control Gel (N = 114) n (%) All Patients (N = 223) n (%) RDEB RDEB, Generalized Severe 62 ( 56.9) 62 ( 54.4) 124 ( 55.6) RDEB, Generalized Intermediate 23 ( 21.1) 16 ( 14.0) 39 ( 17.5) RDEB, Localized 3 ( 2.8) 4 ( 3.5) 7 ( 3.1) RDEB, Other 3 ( 2.8) 2 ( 1.8) 5 ( 2.2) DDEB DDEB 6 ( 5.5) 14 ( 12.3) 20 ( 9.0) JEB JEB, Generalized Severe 0 2 ( 1.8) 2 ( 0.9) JEB, Generalized Intermediate 8 ( 7.3) 9 ( 7.9) 17 ( 7.6) JEB, Localized 1 ( 0.9) 0 1 ( 0.4) JEB, Other 2 ( 1.8) 4 ( 3.5) 6 ( 2.7) EBS EBS, Localized 1 ( 0.9) 1 ( 0.9) 2 ( 0.9) Kindler Kindler 0 0 0 Method of diagnosis Clinical Diagnosis only 25 ( 22.9) 24 ( 21.1) 49 ( 22.0) Immunofluorescence Mapping or Electron Microscopy 16 ( 14.7) 25 ( 21.9) 41 ( 18.4) Genetic Mutation Identified 67 ( 61.5) 62 ( 54.4) 129 ( 57.8) Other 1 ( 0.9) 3 ( 2.6) 4 ( 1.8)

BASELINE TARGET WOUND CHARACTERISTICS 14 Ol e og e l - S 1 0 (N=109) Control Gel (N=114) All Patients (N=223) Size of the wound [cm 2 ]: n 109 114 223 Mean (SD) 18.99 (8.640) 19.41 (10.104) 19.20 (9.398) 95% CI Mean (17.35, 20.63) (17.53, 21.28) (17.96, 20.44) Minimum 10.0 10.0 10.0 Median 16.00 15.45 15.60 Maximum 45.6 49.5 49.5 Age of the wound [days]: n 109 113 222 Mean (SD) 124.3 (327.44) 126.4 (459.99) 125.4 (399.54) 95% CI Mean (62.1, 186.5) (40.6, 212.1) (72.5, 178.2) Minimum 21 21 21 Median 39.0 32.0 35.5 Maximum 2920 4745 4745

PRIMARY EFFICACY ENDPOINT

PRIMARY ENDPOINT - PROPORTION OF TARGET WOUNDS WITH FIRST COMPLETE CLOSURE WITHIN 45 DAYS Relative risk [95%CI], 1.44 [1.01, 2.05] Odds ratio [95%CI], 1.84 [1.02, 3.30] *Pre - specified adjustment to account for IDMC interim sample size re - estimation CI, confidence interval; EB, epidermolysis bullosa 30 20 10 0 40 50 O l eo g e l - S 1 0 (n=109) Control gel (n=114) 41.3% 28.9% p=0.013* Proportion of patients with first complete closure of EB target wound within Day 45, % 44% increase in target wound closure with Oleogel - S10 vs control gel 16

RDEB SUBGROUP DRIVES PRIMARY ENDPOINT TREATMENT EFFECT 44.0% 26.2% Relative risk [95%CI], 1.72 [1.14, 2.59] Odds ratio [95%CI], 2.52 [1.27, 4.98] p=0.008* 10% 0% 2 0 % 3 0 % 4 0 % 5 0 % 6 0 % Oleogel - S10 (n=91) Control Gel (n=84) Proportion of patients with first complete closure of EB target wound within Day 45, % O leoge l - S 1 0 (n=91) Control gel (n=84) 50.0% 50.0% Oleogel - S10 (n=6) Control Gel (n=14) p=0.844* O leoge l - S 1 0 (n=6) Control gel (n=14) 18.2% 26.7% Oleogel - S10 (n=11) Control Gel (n=15) p=0.522* O leoge l - S 1 0 (n=11) Control gel (n=15) *Nominal P values DDEB, dominant dystrophic EB; EB, epidermolysis bullosa; JEB, junctional EB; RDEB, recessive dystrophic EB RDEB DDEB JEB 72% increase in target wound closure, in RDEB patients with Oleogel - S10 vs control gel 17

PROPORTION OF TARGET WOUNDS WITH FIRST COMPLETE CLOSURE WITHIN DAY 45 – CONSISTENT EFFECT ACROSS PEDIATRIC PATIENTS Oleogel - S10 (N=109) % CLOSURE Control Gel (N=114) % CLOSURE 0 - < 4 years (n=17) 71.4% 40.0% 4 - <12 years (n=85)* 42.9% 23.3% 12 - <18 years (n=54) 40.0% 24.1% ≥18 years (n=67) 34.3% 37.5% *Largest age group, patients 4 to 12 years old, had a nominal p - value = 0.021 18

SUB - GROUP ANALYSES SHOW CONSISTENCY – PROPORTION OF TARGET WOUNDS WITH FIRST COMPLETE CLOSURE WITHIN D45 0 1 2 3 < -- Control Gel | Oleogel - S10 -- > Odds Ratio [95% CI] Odds Ratio Subgroup 2.5 2 [1.2 7 , 4.98 ] 1.25 [0.15 , 10.70] 0.5 4 [0.0 8 , 3.58 ] 1.5 9 [0.8 2 , 3.11 ] 6.38 [0.69 , 58.95] 4.55 [0.46 , 45.46] 2.56 [0.33 , 20.03] 3.2 6 [1.1 6 , 9.12 ] 1.69 [0.48 , 5.90 ] 0.86 [0.31 , 2.43 ] 1.68 [0.79 , 3.56 ] 2.26 [0.87 , 5.89 ] 1.64 [0.86 , 3.10 ] N E 1.50 [0.07 , 32.41] 9.00 [0.51 ,159.15] 1.49 [0.48 , 4.62 ] 3.01 [0.98 , 9.23 ] 0.8 2 [0.2 7 , 2.52 ] 3.53 [1.05 , 11.88] 1.1 7 [0.4 2 , 3.24 ] 1.3 2 [0.4 6 , 3.78 ] 4 5 6 7 8 9 1 0 EB SUBTYPE 19 RDE B DDE B JE B SIZE OF TARGET WOUND 10 to <20 cm² 20 to <30 cm² 30 to 50 cm² AGE GROUP 0 - <4 years 4 - <12 years 12 - <18 years >= 18 years GENDE R MAL E FEMAL E RAC E WHIT E BLACK OR AFRICAN AMERICAN ASIA N OTHE R NUTRITIONAL STATUS (ALBUMIN) <= 1st Tertile 1st - 2nd Tertile > 3rd Tertile ANAEMIA (HAEMOGLOBIN) <= 1st Tertile 1st - 2nd Tertile > 3rd Tertile

SECONDARY EFFICACY ENDPOINTS

KAPLAN - MEIER SURVIVAL CURVE SHOWING SEPARATION IN TARGET WOUND CLOSURE AROUND DAY 30 AND DIFFERENCE NARROWING AROUND DAY 90 *Pre - specified adjustment to account for IDMC interim sample size re - estimation CI, confidence interval; EB, epidermolysis bullosa 0 . 2 0 0 . 4 0 . 6 0 . 8 1 Probability of target wound closure 0 7 14 30 45 60 Time to first complete closure of target wound, days 90 50.5% of patients treated with Oleogel - S10 and 43.9% with control gel had target wound closure (p=0.296) within D90 Difference in time to wound healing over the 90 - day double - blind period in the two arms was not statistically significant (log - rank test, p=0.302) O l eoge l - S 1 0 Control 41.3% of patients treated with Oleogel - S10 had complete target wound closure vs. 28.9% with control gel (p=0.013*) within D45 Oleogel - S10, n 109 109 104 82 65 57 36 Control gel, n 114 113 113 91 80 68 41 21

TIME TO FIRST CLOSURE IN WOUNDS THAT CLOSE DURING 90 DAY DBP TIME TO FIRST CLOSURE (DAYS) Oleogel - S10 (N=109) Control Gel (N=114) Mean (SD) 95% CI 37.7 days (21.65) [31.9, 43.6] 44.5 days (26.15) [37.1, 51.9] Median (min - max) 33.0 (10 - 95) 39.0 (15 - 96) In wounds that achieve complete closure, Oleogel - S10 treatment associated with shorter time 22

TIME TO FIRST COMPLETE CLOSURE OF EB TARGET WOUND WITHIN D90 – BY EB SUBTYPE 23 RDEB DDEB JEB Oleogel - S10 (N=91) Control Gel (N=84) Oleogel - S10 (N=6) Control Gel (N=14) Oleogel - S10 (N=11) Control Gel (N=15) Closure 52.7% 44.0% 66.7% 57.1% 18.2% 33.3% Time to first complete closure (days) Mean (SD) 37.9 (20.76) 46.9 (27.31) 28.8 (19.75) 31.0 (14.68) 24.0 (15.56) 48.0 (29.18) 95% CI Mean (31.9, 44.0) (37.8, 56.1) ( - 2.7, 60.2) (18.7, 43.3) ( - 115.8, 163.8) (11.8, 84.2) Minimum - maximum 14 - 95 15 - 96 10 - 56 15 - 58 13 - 35 15 - 94 Median 33.5 45.0 24.5 29.5 24.0 47.0 Log - rank Test p - value 0.175 0.890 0.382

PROCEDURAL PAIN REDUCTION WAS OBSERVED WITH OLEOGEL - S10 (PATIENTS ≥ 4 YEARS OF AGE) 0 . 0 - 0.2 - 0.4 - 0.6 - 0.8 - 1.0 - 1.2 - 1.4 - 1.6 D 1 4 D 3 0 D 4 5 D 6 0 D 9 0 Mean change from baseline 206 patients ≥ 4 years of age used Wong - Baker FACES pain rating scale to assess the degree of pain experienced during their dressing change . Improvement observed was greater with Oleogel - S10 treatment. Oleogel - S10, n 90 90 84 84 76 Control gel, n 95 90 85 86 78 14 30 90 45 D a ys 0 60 O l eo g e l - S 1 0 Control gel p=0 . 02* p=0 . 051* Wong - Baker FACES pain rating scale Oleogel - S10 (n=98 patients) : BL mean 3.7 (SD 3.08) Control gel (n=100 patients) : BL mean 3.0 (SD 2.95) 24 *Nominal P values

PR OCEDURAL PAIN IN PATIENTS < 4 YEARS OF AGE ASSESSED BY INVESTIGATOR 25 Oleogel - S10 7 7 7 5 7 7 Control 10 10 8 8 8 6 2 1 0 - 1 - 2 - 3 3 D0 D 1 4 D 3 0 D 4 5 D 6 0 D 9 0 Mean change from baseline O l eoge l - S 1 0 Control Face, Legs, Activity, Cry, Consolability (FLACC) Pain Rating Scale

REDUCTION IN TOTAL BODY WOUND BURDEN (EBDASI) WITH OLEOGEL - S10 0 - 0 . 5 - 1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 D 0 D 3 0 D 6 0 D 9 0 Mean change from baseline EBDASI, Epidermolysis Bullosa Disease Activity and Scarring Index Total body wound burden based on EBDASI (skin index activity) demonstrated an improvement with Oleogel - S10 O l eoge l - S 1 0 Control gel EB Disease Activity and Scarring Index Oleogel - S10, n 108 99 91 84 Control gel, n 113 99 96 85 0 30 60 90 D a ys 26

REDUCTION IN TOTAL BODY SURFACE AREA OF EB PARTIAL THICKNESS WOUNDS WITH OLEOGEL - S10 0 - 0 . 5 - 1 - 1 . 5 - 2 - 2 . 5 - 3 - 3 . 5 - 4 - 4 . 5 - 5 D 0 D 3 0 D 6 0 D 9 0 BSAP, body surface area percentage The percentage of the total body surface with partial thickness wounds reduced (BSAP using Lund and Browder) O l eoge l - S 1 0 Control gel Body Surface Area Percentage O l eoge l - S 10 , n 109 98 92 86 113 98 96 85 Control gel, n 0 30 60 90 D a ys 27

INCIDENCE AND SEVERITY OF TARGET WOUND INFECTION 28 Ol eoge l - S1 0 (n=109) n(%) Control gel (n=114) n(%) Infection 3 (2.8) 5 (4.4) Severity of wound infection 1 4 Mild 1 (100) 0 (0) Moderate 0 3 (75) Severe 0 (0) 1 (25) Life - threatening 0 (0) 0 Death 0 (0) 0

ITCH ASSESSED IN PATIENTS ≥14 YEARS OF AGE: MEAN CHANGE AT ≥1 TIMEPOINT ACROSS SIX DOMAINS EVALUATED - 1 2 - 1 0 - 8 Duration - 6 - 4 - 2 0 2 - 1 2 - 1 0 - 8 - 6 Distress - 4 - 2 0 2 Oleogel - S10 Control - 1 2 - 7 - 2 Frequency - 1 2 - 1 0 - 8 - 2 0 2 S e v e rity - 6 - 4 Day 30 Day 60 Day 90 Day 30 Day 60 Day 90 - 1 2 - 1 0 - 8 - 6 Surface area - 4 - 2 0 2 - 1 2 - 1 0 - 8 Consequences - 6 - 4 - 2 0 2 100 patients were ≥ 14 years of age, used the Leuven Itch Questionnaire. Improvement observed, however itch is multi - faceted and hence degree of change inconsistent between the 6 domains. 29

ITCH PATIENT REPORTED OUTCOME ≥4 YEARS TO <13 YEARS OF AGE: MODEST IMPROVEMENT, NO BENEFIT OBSERVED WITH OLEOGEL - S10 - 0.24 - 0.96 - 0.33 - 1 - 0.44 - 1 - 1 . 2 - 1 - 0 . 6 - 0 . 8 - 0 . 4 0 - 0 . 2 O l eo g e l - S 1 0 (n=46) Control gel (n=51) O l eo g e l - S 1 0 (n=46) Control gel (n=50) O l eo g e l - S 1 0 (n=39) Control gel (n=43) Mean change in Itch Man Scale score Day 90 Day 30 Day 60 106 patients ≥ 4 years to < 13 years of age assessed degree of itch using Itch Man tool (a single overall impression at each visit). Overall modest improvement, however control gel does slightly better than Oleogel - S10. 30

SAFETY DATA

EASE SAFETY SUMMARY DOUBLE BLIND PERIOD: OLEOGEL - S10 WAS WELL TOLERATED Adverse event category Ole og el - S 1 0 (n=109), n (%) Control gel (n=114), n (%) All Patients (N=223), n (%) Patients with any Adverse Events (AEs) 89 (81.7) 92 (80.7) 181 (81.2) Mild AEs (grade 1) 46 (42.2) 41 (36.0) 87 (39.0) Moderate AEs (grade 2) 30 (27.5) 45 (39.5) 75 (33.6) Severe AEs (grade 3/4) 13 (11.9) 6 ( 5.3) 19 ( 8.5) Any related AEs 27 (24.8) 26 (22.8) 53 (23.8) Any AE leading to study withdrawal 3 (2.8) 2 (1.8) 5 (2.2) The most frequently reported AEs were wound complication (61.5% vs 53.5%), pyrexia (8.3% vs 13.2%), wound infection (7.3% vs 8.8%), pruritus (7.3% vs 5.3%) and anaemia (7.3% vs 3.5%) 32

EASE SAFETY SUMMARY DOUBLE BLIND PERIOD: LOW NUMBER OF SERIOUS ADVERSE EVENTS IN A COMPROMISED PATIENT POPULATION Adverse event category Ol eoge l - S1 0 (n=109) n (%) Control gel (n=114) n (%) All Patients (N=223) n (%) Patients with any serious adverse events (AEs) 7 (6.4) 5 (4.4) 12 (5.4) Any serious AEs leading to study withdrawal 2 (1.8) 0 2 (0.9) Any serious related AEs 1 (0.9) 0 1 (0.4) Any serious AEs leading to death 0 0 0 Low number of patients experienced serious adverse events, of which only 1 was considered to be related to Oleogel - S10 33

CONCLUSIONS • Largest Phase 3 RCT performed in the EB patient population • The primary endpoint demonstrated a statistically significant acceleration of target wound healing by day 45 in patients treated with Oleogel - S10 vs control gel (p=0.013)* • The RDEB sub - group was observed to experience a greater benefit when treated with Oleogel - S10 than the overall population (nominal p=0.008) • Favourable trends were evident among secondary endpoints including change in procedural pain, EBDASI score and BSAP • Oleogel - S10 had a reassuring safety profile and was well tolerated when compared with control gel Oleogel - S10 represents a potentially important advancement for patients and families living with this intractable skin disease 34 *Pre - specified adjustment to account for IDMC interim sample size re - estimation

ACKNOWLEDGEMENTS Thank you to all the patients, their carers and the investigators across these countries for participating! 58 sites initiated in 28 countries, 223 patients EASE clinical study (BEB - 13) was sponsored by Amryt Research Limited 35

FILSUVEZ® - US & EUROPEAN ANTICIPATED REGULATORY TIMELINES NDA TIMELINE – FDA – 6 MONTH PRIORITY REVIEW AND ROLLING NDA 2020 2021 January December January December Apr - Type C Jun - Module 3 Sept – Positive Dec - m ee t i n g C M C r eque s t T o p L i n e P has e p r e - NDA completed for priority 3 Results w/ meeting review primary submitted endpoint met MAA TIMELINE – EM Nov - Anticipated Approval Date Mar - Initial May - Filing Nov – Priority submission Date Review Voucher A – ACCELERATED ASSESSMENT 2020 2021 January December January December Jun – MAA Letter Sep – Nov – MAA Dec – Accel o f I n t en t s ub m itt e d R appo r t eu r s P r e - A ss e ss m en t to EMA assigned by submission request to C CHMP meetings Mar - Initial Aug - Sep - List of Oct - CHMP Dec - e r a t e d sub m i ss i o n J u n - L i s t o f S ub m i ss i o n o f O u t s t and i n g O p i n i o n E u r opea n ( A cc e l e r a t e d Q ues t i on s r e s pon s e s t o I ssue s ( Lo O I ) C o mm i ss i o n HMP Review (LoQ) LOQ received and Decision S chedu l e ) r e c e i v e d r e s pon s e s submitted 36

Q&A SESSION WITH KOLs

FILSUVEZ ® LAUNCH READINESS David Allmond, Chief Business Officer - Amryt

A G ENDA 39 • Amryt a global commercial stage rare disease company • The severity of EB & the EASE trial in context • A significant opportunity for growth • Launch strategy & key activities • Next steps and key takeaways

AMRYT IS A GLOBAL COMMERCIAL STAGE COMPANY DELIVERING ON OBJECTIVES & CREATING OPERATING LEVERAGE 40 FY 2020 revenue guidance of between $170 - 175M vs $154.1M* 2019 EBITDA profitable in H1 2020. $67.1M in cash as of June 30, 2020** Expansion opportunities for existing products in new indications & geographies Pipeline of new potential therapies in rare & orphan diseases Potential for FILSUVEZ ® approval in EB in 2021 Q3 results will be announced November 5, 2020 Experienced management team in rare diseases Established, scalable global commercial and medical infrastructure to be leveraged for future products Two marketed global rare disease products, metreleptin & lomitapide Global Footprint Commercial Products Growth & Profit Value Drivers *Reflects pro forma revenues for the combined group ** Unaudited

AMRYT KEY MILESTONES TO VALUE CREATION 41 MILESTONE TIMING* STATUS Acquired Birken 2015 ض Acquired Lojuxta EMEA 2016 ض Acquired AP103 2018 ض Myalepta EU launch 2018 ض Acquired Aegerion 2019 ض EASE double blind completion 2020 ض Initiate Lojuxta pediatric study Q2 2020 ض FCS POC topline data Q4 2020 FILSUVEZ ® FDA & EMA filings Mar 2021 Initiate US PL study 2H 2021 FILSUVEZ ® approval and launch** Q4 2021 US & Q1 2022 EU Priority Review Voucher granted Q4 2021 US** *Future event timing based on management estimates **If FILSUVEZ approved by regulatory authorities

EPIDERMOLYSIS BULLOSA (EB) JUNCTIONAL • Most severe form of EB • Extensive blistering all over body • Often fatal in early childhood DYSTROPHIC • Severe form of EB • Fusion of fingers and toes • Possibility of skin cancer • Mildest form of EB • Episodic blistering SIMPLEX D i seas e sever ity E B IS A VERY SEVERE DEBILITATING DISEASE WITH NO APPROVED TREATMENT 42 • Management of EB is to provide intensive wound care, manage pain and itch and to address complications that arise from internal and external wounds • Patients and caregivers are responsible for the frequent bandage changes. Although all patients see community doctors, the most severe patients also see EB specialists • There is very high unmet need for both wound - healing and disease - modifying therapies for EB patients, especially the most severe forms such as RDEB • There are no approved treatments for the management of EB wounds

KEY EB RESEARCH PRIORITIES EXPRESSED BY PATIENTS AND CLINICIANS 1 43 Which wound care method obtains better outcomes (improved healing, decrease in pain, improved quality of life, decrease in smell, prevention of infection) in patients with DEB? What is the best treatment to control itch in patients with DEB? What is the best pain control strategy to decrease pain during wound care and bathing in patients with DEB? How much does management in reference centers help patients with DEB? How effective is a tumor early diagnosis protocol to decrease mortality, amputations, and disability in patients with DEB? What are the long - term results of syndactyly surgery? Which is the best technique? How often should it be performed? Which is the most effective method to prevent or delay syndactyly in patients with DEB? What role might tissue engineering have in treating wounds in patients with DEB? What role might stem cell therapy and bone - marrow transplantation play in treating DEB? What role might growth hormone play in treatment of impaired growth and pubertal delay in patients with DEB? 1 2 3 4 5 6 7 8 9 10 Potential for FILSUVEZ® to offer benefit if it is approved 1 Adapted from Current dystrophic EB research does not match research needs perceived by patients and clinicians, Paula Davila - Seijo MD. J AM ACA Dermatol, Nov 2014

THE SIGNIFICANCE OF THE EASE TRIAL TO AMRYT AND THE EB COMMUNITY 44 • EASE trial is the largest ever conducted randomized controlled trial in EB across 55 sites in 28 countries – Study design was agreed with FDA and EMA – The trial has met its primary endpoint • Regulatory path is clear with fast - track designation in US and potential for accelerated review in EU • Subject to FDA & EMA reviews, anticipated approval in US Q4 2021 and EU Q1 2022 • Regulatory approval in the US may lead to a pediatric rare disease voucher • FILSUVEZ ® has the potential to be the first ever approved product in EB • FILSUVEZ ® , if approved, is anticipated to provide an important treatment option for the management of wounds in patients with EB* *The EASE trial was conducted in patients with DEB and JEB

HIGHLY CONCENTRATED MARKET WITH 56 KEY CENTRES IN EU5, US AND JAPAN. < 100 KEY PHYSICIANS MAPPED TO THESE CENTRES 45 GLOBAL distribution of centres taking care of EB patients makes reach entirely feasible and economically attractive Global patient mapping exercise underway NUMBER OF PATIENTS <50 patients 50 - 100 patients 100 - 200 patients 200 - 400 patients >400 patients

INSIGHTS INTO MARKET LANDSCAPE 1 46 EB Prevalence DEB & JEB X Treatment Rates X Peak Penetration X Adoption Ramp X Wound BSA and Penetration X Dosing and Frequency X Market Access & Compliance Cuts X Price • Incidence among live births 1:20,000 2 , multiplied by life expectancy per EB sub - type, generates total EB prevalence of 30/million in the general population of which ~31% are DEB & JEB patients 1 – Resulting prevalence of ~14,100 for DEB & JEB 3 • 100% wound treatment rate for DEB & JEB • Peak penetration: 70 - 75% into severe forms (Herlitz & RDEB), 50% into DDEB & JEB - non Herlitz • Launch in Q4 2021 US & Q1 2022 Europe • 5 - year ramp based on orphan drug analogs • Wound BSA: 50% for JEB Herlitz, 20 - 35% for RDEB, 2 - 7% for DDEB • Wound area penetration: Applied to 80 - 100% of wounds in DEB & JEB • Addressable wound area x 0.5 - 1mm thickness 4 • ~2.5 dressing changes per week, or 130 dressing changes a year • 95% market access • 85% compliance • Orphan pricing 1 Health Advances market research, 13 th Feb 2019; 2 Debra US; 3 Includes key markets in which Amryt operates (US, EMEA, LATAM & Canada) plus geographic expansion in Asia Pacific (Japan, South Korea, Taiwan, Singapore, Hong Kong, Australia); 4 Management estimate based on EASE trial experience

CUSTOMER FACING INFRASTRUCTURE WILL REQUIRE MODEST INCREMENTAL INVESTMENT TO DRIVE GLOBAL ACCESS AND DEMAND 47 Pending markets Current markets US Sales & Marketing Medical Affairs Market Access Patient Services LATAM Sales & Marketing Medical Affairs Ex - US & HQ Sales & Marketing Medical Affairs Market Access Patient Advocacy Support Functions

GLOBAL STRATEGIC IMPERATIVES TO GUIDE LAUNCH READINESS ACTIVITIES* 48 *If FILSUVEZ ® were to be approved by regulatory authorities EDUCATE POSITION E N G A G E 1 2 3 Strategic Objectives* Ensure stakeholders understand the potential of FILSUVEZ ® Ensure HCPs and patients understand the correct utilization of FILSUVEZ ® Payors and health systems provide access to FILSUVEZ ® based on a compelling value proposition and narrative FILSUVEZ ® becomes an important therapy for EB wound care ACCESS 4

49 EXAMPLES OF GENE & CELL THERAPIES IN DEVELOPMENT 1 • Gene and cell therapies not anticipated to offer a complete cure 2 • FILSUVEZ ® , if approved, has the potential to become an important treatment in wound care therapy 2 • FILSUVEZ ® anticipated to co - exist with these potential therapies, should they come to market 2 1 Company websites & clinicaltrials.gov; 2 Health Advances Research, February 13 th , 2019 D eve l op m en t Product EB - 101 FCX - 007 (D - Fi) AP103 B - VEC MoA HSV1 Gene therapy COL7A1 - corrected keratinocyte skin graft COL7A1 - corrected autologous fibroblast Non viral vector based gene therapy RoA & Dosing Weekly topical application until wound closure Surgical attachment Intradermal injection to wounds Topical application Development Phase & Target Indication Ph3 ongoing DEB Ph3 ongoing RDEB Ph3 ongoing RDEB Pre - clinical

EMPLOYING OUR RARE DISEASE PHILOSOPHY WHICH INCORPORATES A MULTIDISCIPLINARY APPROACH TO WRAP AROUND THE PATIENT Patient Advocacy & support 50 Marketing Market Access Medical Affairs Evidence generation Scientific platform Disease education Scientific rationale & MoA Expanded Access Programs Peer to peer scientific exchange International congress plans KOL engagement Market Insights Brand strategy development Brand narrative development Brand identity Promotional platform Packaging design Internal training Payer/HTA evidence generation Global pricing strategy Value proposition Value platform and payor tools Reimbursement strategy Relationship development with EB advocacy groups Patient education Patient support programs Patient access Engagement on health policy

AMRYT HAS STRONG RELATIONSHIPS WITH THE WELL ESTABLISHED EB P ATIENT ADVOCACY, SCIENTIFIC & RESEARCH COMMUNITY Working with key stakeholder in the EB community can result in a number of potential benefits: • Gaining patient insights • Increasing disease awareness • Providing patient education • Supporting patient access 51

GO TO MARKET STRATEGY & PRIORITISATION* • • • • US anticipated to be first market in Q4 2021 to launch following FDA approval • EU would launch immediately following EMA approval in Germany followed by price & reimbursement negotiations in Italy, France, Spain, UK and then sequentially in other EU22 markets Potential for rest of world regulatory filings and named patient sales in GCC, Turkey, Israel, Russia, LATAM & Canada “New territories” go to market strategy to be defined - Asia Pacific including Japan, Australia, China, Taiwan & S Korea The FILSUVEZ® patent portfolio provides patent protection in both the US and EU into 2025 and 2030 respectively and, if FILSU VEZ ® is approved in 2021, orphan exclusivity to 2028 in the US and 2031 in the EU. A further filed international patent application covering future FILSUVEZ® indications, if granted, would provide worldwide protection for such indications until 2039. 52 2021 2022 2023 2024 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 FILSUVEZ ® US L AUNCH EU LAU NCH REST O F WORLD NEW TE RRITORI ES * Anticipated events if FILSUVEZ ® were to be approved by regulatory authorities

NEXT STEPS IN PLANNING FOR SUCCESS 53 • Gather deeper market insights through market research & stakeholder engagement • Regulatory filings for FDA/EMA and prioritized plan for other key markets to leverage these files • Key medical affairs & market access readiness activities to be implemented Q4 2020 through 2021 • In country and “above country” launch plans to be further developed following positive trial read out • Manufacturing scale up, second source and supply chain readiness to meet demand • New territories “go to market” strategy to be fully defined, ready for implementation • Lifecycle plans “beyond EB” to be developed to maximize asset value in line with patent term

KEY TAKEAWAYS 54 • Amryt is a commercial stage company with a track record of delivering on commercial targets • EB is a severe debilitating disease for which there are no approved treatments • The EB market is highly concentrated and feasible to reach with limited incremental resources • There is a significant market opportunity if FILSUVEZ ® were approved by regulatory authorities • Amryt is developing robust launch plans* to access the opportunity based on our commercial infrastructure, rare disease philosophy, experience and playbook • Manufacturing scale up & supply chain plan in place to ensure adequate drug supply to meet demand • FILSUVEZ ® benefits from strong patent protection and exclusivity enabling Amryt to create significant value in EB and beyond • Amryt is building a global EB Franchise to serve patients in desperate need of new treatments *If FILSUVEZ ® were to be approved by regulatory authorities

Q&A SESSION

FINANCIAL CALENDAR • Amryt will report Q3 results on November 5, 2020 at 1200 GMT / 0700 EST • Amryt will host a conference call and webcast for analysts and investors on November 5 at 1430 GMT / 0930 EST. • Webcast Player URL: https://edge.media - server.com/mmc/p/dor9m4ay • Dial in details: Confirmation code: 2865629 – US +1 646 787 1226 – UK +44 (0) 203 009 5709 – Ire +353 (1) 506 0626 • Full details at amrytpharma.com or ema il ir@amrytpharma.com 56